Table 1.
An overview of previously published cutting-edge research.
| Year | Method | Skin disorder | Accuracy |
|---|---|---|---|
| 2021 | CNN [16] | Melanoma | 97.16% |
| 2021 | RCNN [14] | Melanoma | 96.3% (ISBI2016), 94.8% (ISBI2017), 88.5% (HAM1000) |
| 2021 | CNN [17] | Dermatofibroma, benign keratosis, basal cell carcinoma, melanoma, melanocytic nevi, actinic keratosis, and vascular | 90.67% |
| 2021 | CNN [19] | Melanoma | 92.18% |
| 2021 | RF and KNN [20] | Psoriasis | 98.6% (RF) and 92.6% (KNN) |
| 2019 | CNN [21] | Psoriasis | 94.80% |
| 2018 | CNN [15] | Melanoma | 82.4% |
| 2018 | CNN [22] | Psoriasis | 95.17% |